Pandion Therapeutics Holdco LLC (34) | Uncategorized (10)

Recent Contracts

Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 12, 2021)
Confidential Disclosure-In Agreement, dated as of April 9, 2018, between Pandion Therapeutics, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 12, 2021)
Amendment No. 1 to Confidential Disclosure-In Agreement, dated as of December 16, 2019, between Pandion Therapeutics, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 12, 2021)
Amendment No. 2 to the Confidential Disclosure-In Agreement, dated as of December 18, 2020, between Pandion Therapeutics, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 12, 2021)
Amendment No. 3 to the Confidential Disclosure-In Agreement, dated as of February 13, 2021, between Pandion Therapeutics, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 12, 2021)
Exclusivity Agreement, dated as of February 9, 2021, between Pandion Therapeutics, Inc. and Merck Sharp & Dohme Corp (Filed With SEC on March 12, 2021)
Form of Plan of Conversion (Filed With SEC on July 13, 2020)
Letter Agreement, dated July 8, 2020, by and between the Registrant and Vikas Goyal (to be effective upon the effective date of the Registration Statement) (Filed With SEC on July 13, 2020)
Letter Agreement, dated July 10, 2019, as amended, by and between the Registration and Anthony Coyle, Ph.D (Filed With SEC on June 26, 2020)
Simple Agreement for Future Equity, dated June 24, 2020, by and between the Registrant and Versant Vantage I, L.P (Filed With SEC on June 26, 2020)